First launch for GSK's combination BPH drug Combodart

GlaxoSmithKline's combination benign prostatic hyperplasia (BPH) drug Combodart (dutasteride 0.5mg/tamsulosin hydrochloride 0.4mg) has been launched in the UK, its first market.

GlaxoSmithKline's combination benign prostatic hyperplasia (BPH) drug Combodart (dutasteride 0.5mg/tamsulosin hydrochloride 0.4mg) has been launched in the UK, its first market.

The once-daily pill combines GSK's 5-alpha reductase inhibitor Avodart (dutasteride), which was launched in the UK in 2003, with the...

More from Immunological

More from Therapeutic Category

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.